Holocene Advisors LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Holocene Advisors LP acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, Holdings Channel.com reports. The firm acquired 151,733 shares of the biopharmaceutical company’s stock, valued at approximately $85,315,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Osaic Holdings Inc. lifted its stake in Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after buying an additional 6,073 shares during the period. Robeco Institutional Asset Management B.V. grew its position in shares of Regeneron Pharmaceuticals by 153.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after buying an additional 73,176 shares during the period. PGGM Investments grew its position in shares of Regeneron Pharmaceuticals by 9.7% during the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after buying an additional 8,187 shares during the period. Sound Shore Management Inc CT bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $64,677,000. Finally, Rakuten Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $33,121,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $756.91 on Tuesday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $769.61 and a two-hundred day simple moving average of $696.93. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a market capitalization of $80.02 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 2.00 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the firm earned $12.07 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,274 shares of company stock worth $4,142,738 over the last 90 days. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Canaccord Genuity Group increased their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Evercore raised their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Finally, Truist Financial decreased their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.